Evidence map›Paper›PMID 41724834›Full record

ArticleArchives of microbiology2026

Lactilactobacillus curvatus TH19-7: a broad-spectrum antimicrobial probiotic targeting skin pathogens and mitigating infection-associated dermal damage in vitro.

Trang Thi Minh Nguyen, Xiangji Jin, Qiwen Zheng, Gyeong-Seon Yi, Jae-Woo Kim, Mi-Ju Kim, Tae-Hoo Yi

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Trang Thi Minh NguyenGraduate School of Biotechnology, Kyung Hee University, 1732 Deogyeong-daero, Giheung-gu, Yongin-si, 17104, Republic of Korea.
Xiangji JinDepartment of Dermatology, School of Medicine, Kyung Hee University, 23 Kyungheedae-ro, Dong-daemun, Seoul, Republic of Korea.
Qiwen ZhengGraduate School of Biotechnology, Kyung Hee University, 1732 Deogyeong-daero, Giheung-gu, Yongin-si, 17104, Republic of Korea.
Gyeong-Seon YiDepartment of Biopharmaceutical Biotechnology, Graduate School, Kyung Hee University, 1732 Deogyeong-Daero, Giheung-gu, Yongin-si, 17104, Republic of Korea.
Jae-Woo KimDepartment of Biopharmaceutical Biotechnology, Graduate School, Kyung Hee University, 1732 Deogyeong-Daero, Giheung-gu, Yongin-si, 17104, Republic of Korea.
Mi-Ju KimInstitute of Life Sciences & Resources and Department of Food Science & Biotechnology, Kyung Hee University, Yongin, 17104, Republic of Korea.
Tae-Hoo YiGraduate School of Biotechnology, Kyung Hee University, 1732 Deogyeong-daero, Giheung-gu, Yongin-si, 17104, Republic of Korea. drhoo@khu.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective management of skin infections requires antimicrobial agents that can eradicate pathogens and mitigate associated tissue damage. This in vitro study evaluates the potential of Lactilactobacillus curvatus TH19-7, isolated from kimchi, as a safe and broad-spectrum antimicrobial probiotic. The selected lactic acid bacterium was identified by 16S rRNA sequencing and biochemical profiling, followed by in vitro evaluation of antimicrobial activity (MIC/MBC), cellular morphology (SEM), safety (antibiotic susceptibility, hemolysis, bile salt hydrolase activity, and D-lactic acid production), antioxidant capacity (DPPH and ABTS assays), and anti-inflammatory effects assessed by macrophage viability and NO inhibition. The strain demonstrated significant bactericidal activity, with its cell-free supernatant inhibiting the growth of key cutaneous pathogens, including Staphylococcus aureus, Staphylococcus epidermis, Cutibacterium acnes, Pseudomonas aeruginosa, Escherichia coli (E. coli), and Candida albicans by 64.7-83.5% at 2.5 mg/mL. Minimum Inhibitory and Bactericidal Concentrations (MIC/MBC) confirmed high potency, with low MICs of 1.25 mg/mL against several targets. Crucially, scanning electron microscopy revealed that the antimicrobial mechanism involves direct cellular lysis and severe membrane deformation in bacterial cells, particularly with E. coli, with complete cell disruption. Beyond pathogen eradication, the strain exhibited significant radical scavenging capacity (ABTS IC₅₀ = 39.1 µg/mL) and suppressed nitric oxide production in macrophages by 34.8%, indicating potential to mitigate oxidative and inflammatory tissue damage. Furthermore, L. curvatus TH19-7 displayed a strong safety profile, demonstrating a non-hemolytic (γ-hemolytic) phenotype, susceptibility to a broad range of clinically relevant antibiotics, minimal D-lactate production, and demonstrated tolerance to simulated gastrointestinal stress conditions. These findings position L. curvatus TH19-7 as a promising topical probiotic that directly eliminates pathogens through membrane disruption and concurrently aid tissue recovery through immunomodulatory and antioxidant activities.

Indexed as

Anti-Infective AgentsProbioticsAnimalsAntioxidantsCandida albicansEscherichia coliHumansMacrophagesMiceMicrobial Sensitivity TestsPseudomonas aeruginosaRNA, Ribosomal, 16SSkinStaphylococcus aureusAnti-Infective AgentsAntioxidantsRNA, Ribosomal, 16SAnti-inflammatoryAntimicrobialAntioxidantLactilactobacillus curvatusProbioticSkin infection

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.